Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels
This study has been completed.
Sponsored by: BioMarin Pharmaceutical
Information provided by: BioMarin Pharmaceutical
ClinicalTrials.gov Identifier: NCT00225615
  Purpose

The primary objective of this trial is to evaluate the safety and tolerability of long-term Phenoptin treatment in subjects with PKU.


Condition Intervention Phase
Phenylketonurias
Drug: sapropterin dihydrochloride
Phase III

Genetics Home Reference related topics: argininosuccinic aciduria citrullinemia N-acetylglutamate synthase deficiency ornithine translocase deficiency phenylketonuria tetrahydrobiopterin deficiency
MedlinePlus related topics: Phenylketonuria
Drug Information available for: Sapropterin Sapropterin dihydrochloride Phenylalanine
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels

Further study details as provided by BioMarin Pharmaceutical:

Primary Outcome Measures:
  • Primary objective:
  • - To evaluate the safety and tolerability of long-term Phenoptin treatment in subjects with PKU.

Secondary Outcome Measures:
  • Secondary objectives:
  • To compare the safety and tolerability of three different doses of Phenoptin treatment in subjects with PKU.
  • To determine the effect of various doses of Phenoptin on blood phenylalanine (Phe) levels.
  • To evaluate the population pharmacokinetics of Phenoptin.
  • To evaluate the ability of Phenoptin to reduce phenylalanine (Phe) levels over a 24-hour period.
  • To evaluate the persistence of benefit of Phenoptin treatment in the subject population as evidenced by long-term control of blood Phe levels.

Estimated Enrollment: 100
Study Start Date: November 2005
Study Completion Date: June 2006
  Eligibility

Ages Eligible for Study:   8 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 8 years of age and older
  • Prior successful participation in Study PKU-003
  • Willing and able to provide written informed consent or assent and written informed consent (if required) by a parent or legal guardian
  • For females of child-bearing potential only: Negative urine pregnancy test within 24 hours prior to enrollment. Women using acceptable birth control measures must agree to continue to use those measures while participating in the study
  • Willing and able to comply with study procedures
  • Willing to continue current diet unchanged while participating in the study

Exclusion Criteria:

  • Perceived to be unreliable or unavailable for study participation or, if under the age of 18, have parents or legal guardians who are perceived to be unreliable or unavailable
  • Withdrew from, or otherwise did not successfully complete, study PKU-003, except for subjects who were removed from the study because their blood Phe exceeded the alert level
  • Expected to require any investigational agent or vaccine prior to completion of all scheduled study assessments
  • Pregnant or breastfeeding, or planning pregnancy
  • Concurrent disease or condition that would interfere with study participation or safety (e.g., seizure disorder, oral steroid-dependent asthma or other condition requiring oral or parenteral corticosteroid administration, or insulin-dependent diabetes)
  • Requirement for concomitant treatment with any drug known to inhibit folate synthesis (e.g., methotrexate)
  • Concurrent use of levodopa
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00225615

Locations
United States, California
Los Angeles, California, United States
Oakland, California, United States
San Jose, California, United States
Sacramento, California, United States
United States, Connecticut
New Haven, Connecticut, United States
United States, Georgia
Atlanta, Georgia, United States
United States, Illinois
Chicago, Illinois, United States
United States, Minnesota
Minneapolis, Minnesota, United States
United States, Missouri
St. Louis, Missouri, United States
United States, New York
New York, New York, United States
United States, Oregon
Portland, Oregon, United States
United States, Texas
Dallas, Texas, United States
United States, Utah
Salt Lake City, Utah, United States
United States, Wisconsin
Madison, Wisconsin, United States
Sponsors and Collaborators
BioMarin Pharmaceutical
Investigators
Study Chair: Alex Dorenbaum, MD BioMarin Pharmaceutical
  More Information

BioMarin Pharmaceutical Inc website  This link exits the ClinicalTrials.gov site

Study ID Numbers: PKU-004
Study First Received: September 22, 2005
Last Updated: April 5, 2007
ClinicalTrials.gov Identifier: NCT00225615  
Health Authority: United States: Food and Drug Administration

Keywords provided by BioMarin Pharmaceutical:
Phenylalanine Hydroxylase

Study placed in the following topic categories:
Metabolism, Inborn Errors
Inborn amino acid metabolism disorder
Metabolic Diseases
Genetic Diseases, Inborn
Amino Acid Metabolism, Inborn Errors
Central Nervous System Diseases
Brain Diseases, Metabolic, Inborn
Phenylketonurias
Metabolic disorder
Brain Diseases
Phenylketonuria
Brain Diseases, Metabolic

Additional relevant MeSH terms:
Nervous System Diseases

ClinicalTrials.gov processed this record on January 16, 2009